Giuseppe Mele, Claudia Romano, Antonella Miccoli, Angelo Santoro, Domenico Pastore
Haematology and Stem Cell Transplant Unit, Ospedale Antonio Perrino, Brindisi, Italy.
Blood and Transfusion Medicine Department, Ospedale Antonio Perrino, Brindisi, Italy.
Leuk Res Rep. 2022;18:100342. doi: 10.1016/j.lrr.2022.100342. Epub 2022 Aug 8.
Myeloma patients are at an increased risk of severe forms of Covid-19. We examined response to mRNA vaccine between myeloma patients (n.127) and healthy volunteers (n.50). Anti-spike IgG antibody were detected in 76.9% of evaluable patients. 23.1% of MM patients failed to respond at two doses of COVID-19 mRNA vaccine. Univariate analyses identified three independent adverse predictive factors of absence of immunological response to COVID-19 vaccine: extreme plasmacytosis ( < 0.001), B2M (p 0.006), and haemoglobin (p 0.008). Multivariate analysis confirmed the extreme plasmacytosis and haemoglobin value as statistically significant variables.
骨髓瘤患者感染重症新型冠状病毒肺炎（Covid-19）的风险增加。我们研究了骨髓瘤患者（127例）和健康志愿者（50例）对mRNA疫苗的反应。在76.9%的可评估患者中检测到抗刺突IgG抗体。23.1%的骨髓瘤患者在接种两剂新冠病毒mRNA疫苗后无反应。单因素分析确定了对新冠病毒疫苗无免疫反应的三个独立不良预测因素：极度浆细胞增多（<0.001）、β2微球蛋白（p=0.006）和血红蛋白（p=0.008）。多因素分析证实极度浆细胞增多和血红蛋白值是具有统计学意义的变量。
